

Special Issue

Immunotherapy in Lung Cancer and Biomarkers of Response

Message from the Guest Editors

Due to the development of immune checkpoint inhibitors, the treatment of lung cancer has experienced a radical change during the last several years, and relevant advances to replace the standard of care are presented every few months. However, the majority of patients do not respond to treatment, and the predictive biomarkers proposed thus far are lacking in accuracy. Furthermore, the mechanistics are not yet clear, and although CD4 and CD8 T cells are considered key players, other cells and molecules might strongly condition the response to immunotherapy. These are unmet needs on which basic and clinical research is spending great effort. In addition, other immunotherapeutic treatments, such as vaccines, antibody-based targeted therapies and adoptive therapies, are being investigated for this disease, and outcomes from small non-randomized trials indicate the feasibility and potential of these approaches. This Special Issue intends to gather work regarding advances in the mechanistics of immunotherapy in NSCLC, as well as novel approaches for the treatment of this disease.

Guest Editors

Dr. Hugo Arasanz Esteban
Oncoimmunology Group, Navarrabiomed, 31008 Pamplona, Spain

Dr. Paula Aldaz Donamaria
Cancer Signaling Group, Navarrabiomed, 31008 Pamplona, Spain

Deadline for manuscript submissions

closed (31 August 2021)



Life

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 6.0
Indexed in PubMed



mdpi.com/si/71666

Life
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
life@mdpi.com

mdpi.com/journal/

[life](https://mdpi.com/journal/)





Life

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
life](https://mdpi.com/journal/life)



About the Journal

Message from the Editor-in-Chief

Life (ISSN 2075-1729) is an international, peer-reviewed open access journal that publishes scientific studies related to fundamental themes in life sciences. Some papers are published individually, while others are submitted for inclusion in special issues with guest editors. You are invited to contribute a research article, essay, or a review to be considered for publication.

Editor-in-Chief

Prof. Dr. Lluís Ribas de Pouplana

Institute for Research in Biomedicine (IRB Barcelona), The Barcelona
Institute of Science and Technology, 08028 Barcelona, Spain

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biology) / CiteScore - Q1 (Paleontology)